[1] Léauté-Labrèze C, Harper JI, Hoeger PH.Infantile haemangioma[J]. Lancet, 2017, 390(10089): 85-94. [2] Léauté-Labrèze C, Dumas De La Roque E, Hubiche T, et al. Propranolol for severe hemangiomas of infancy[J]. N Engl J Med, 2008, 358(24): 2649-2651. [3] 郑家伟, 王绪凯, 秦中平, 等. 口服普萘洛尔治疗婴幼儿血管瘤中国专家共识[J]. 上海口腔医学, 2016, 25(3): 257-260. [4] Chang L, Lv D, Yu Z, et al.Infantile hemangioma: factors causing recurrence after propranolol treatment[J]. Pediatr Res, 2018, 83(1-1): 175-182. [5] Gomez-Acevedo H, Dai Y, Strub G, et al.Identification of putative biomarkers for infantile hemangiomas and propranolol treatment via data integration[J]. Sci Rep, 2020, 10(1): 3261-3278. [6] Caussé S, Aubert H, Saint-Jean M, et al.Propranolol-resistant infantile haemangiomas[J]. Br J Dermatol, 2013, 169(1): 125-129. [7] Xia Y, Wang X, Liu Y, et al.PKM2 is essential for bladder cancer growth and maintenance[J]. Cancer Res, 2022, 82(4): 571-585. [8] Wang S, Fu J, Hao H, et al.Metabolic reprogramming by traditional Chinese medicine and its role in effective cancer therapy[J]. Pharmacol Res, 2021, 170: 105728. [9] Boulos JC, Rahama M, Hegazy MF, et al.Shikonin derivatives for cancer prevention and therapy[J]. Cancer Lett, 2019, 459: 248-267. [10] Laken PA.Infantile hemangiomas: pathogenesis and review of propranolol use[J]. Adv Neonatal Care, 2016, 16(2): 135-142. [11] Kowalska M, Debek W, Matuszczak E.Infantile hemangiomas: an update on pathogenesis and treatment[J]. J Clin Med, 2021, 10(20): 4631-4643. [12] 林思, 秦慧真, 邓玲玉, 等. 紫草素抗肿瘤作用研究进展[J]. 中国实验方剂学杂志, 2022, 28(9): 273-282. [13] 赵莉, 黄景荣, 龚承先, 等. 紫草素对人食管癌TE-1细胞增殖、凋亡和细胞周期的影响及其可能的机制[J].中国肿瘤生物治疗杂志, 2020, 27(8): 889-894. [14] 马畅, 彭国良, 李妍. 紫草素对乳腺癌4T1细胞增殖的抑制作用及其机制研究[J]. 吉林医药学院学报, 2022, 43(2): 85-87. [15] 杨志强, 陈路, 张雅茜, 等. 紫草素通过调节PI3K/AKT途径抑制骨肉瘤生长和作用机制研究[J]. 中国比较医学杂志, 2022, 32(1): 68-74, 96. [16] 刘亚楠, 王炳先, 路臣桂, 等. 紫草素对子宫内膜癌细胞增殖、凋亡和顺铂耐药性的影响[J].中成药, 2021, 43(8): 2219-2224. [17] Huang J, Zhao L, Gong C, et al.Shikonin promotes apoptosis and attenuates migration and invasion of human esophageal cancer cells by inhibiting tumor necrosis factor receptor-associated protein 1 expression and AKT/mTOR signaling pathway[J]. Evid Based Complement Alternat Med, 2021: 5386050. [18] Guo C, He J, Song X, et al.Pharmacological properties and derivatives of shikonin-a review in recent years[J]. Pharmacol Res, 2019, 149: 104463. [19] 朱梦媛, 王汝冰, 周文, 等. 紫草素及其衍生物抗肿瘤作用研究进展[J].药学学报, 2012, 47(5): 588-593. [20] Zheng H, Huang Q, Huang S, et al.Senescence inducer shikonin ROS-dependently suppressed lung cancer progression[J]. Front Pharmacol, 2018, 9: 519-533. |